keyword
MENU ▼
Read by QxMD icon Read
search

Radioiodine treatment

keyword
https://www.readbyqxmd.com/read/28318881/targeted-therapy-in-thyroid-cancer-state-of-the-art
#1
L Valerio, L Pieruzzi, C Giani, L Agate, V Bottici, L Lorusso, V Cappagli, L Puleo, A Matrone, D Viola, C Romei, R Ciampi, E Molinaro, R Elisei
Thyroid cancer typically has a good outcome following standard treatments, which include surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine hormone-suppressive levothyroxine. Thyroid cancers that persist or recur following these therapies have a poorer prognosis. Cytotoxic chemotherapy or external beam radiotherapy has a low efficacy in these patients. 'Target therapy' with tyrosine kinase inhibitors (TKIs) represent an important therapeutic option for the treatment of advanced cases of radioiodine refractory (RAI-R) differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC) and possibly for cases of poorly differentiated (PDTC) and anaplastic thyroid cancer (ATC)...
March 16, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28299283/lenvatinib-for-anaplastic-thyroid-cancer
#2
Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina E Dutcus, Shunji Takahashi
BACKGROUND: Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest lethality. Effective therapy for ATC is an unmet need. PATIENTS AND METHODS: This phase 2, single-arm, open-label study in patients with thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted from 3 September 2012 to 9 July 2015...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28296315/effective-method-of-measuring-the-radioactivity-of-%C3%A2-131i-capsule-prior-to-radioiodine-therapy-with-significant-reduction-of-the-radiation-exposure-to-the-medical-staff
#3
Ulf Lützen, Yi Zhao, Marlies Marx, Thea Imme, Isong Assam, Frank-Andre Siebert, Juraj Culman, Maaz Zuhayra
Radiation Protection in Radiology, Nuclear Medicine and Radio Oncology is of the utmost importance. Radioiodine therapy is a frequently used and effective method for the treatment of thyroid disease. Prior to each therapy the radioactivity of the [ 131I]-capsule must be determined to prevent misadministration. This leads to a significant radiation exposure to the staff. We describe an alternative method, allowing a considerable reduction of the radiation exposure. Two [ 131I]-capsules (A01=2818.5; A02=73...
July 2016: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28294980/microrna-146b-a-novel-biomarker-and-therapeutic-target-for-human-papillary-thyroid-cancer
#4
REVIEW
Chen-Kai Chou, Rue-Tusan Liu, Hong-Yo Kang
Papillary thyroid cancer (PTC) is the most common tumor subtype of thyroid cancer. However, not all PTCs are responsive to current surgical and radioiodine treatment. The well-established clinical prognostic factors include tumor size, lymph node/distal metastasis, and extrathyroidal invasion. The RET/PTC-RAS-BRAF linear molecular signaling cascade is known to mediate PTC pathogenesis. However, whether presence of BRAF mutation, the most common genetic alteration in PTC, can affect PTC behavior and prognosis is controversial...
March 15, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28291381/selimetry-a-multicentre-i-131-dosimetry-trial-a-clinical-perspective
#5
Jonathan Wadsley, Rebecca Gregory, Glenn Flux, Kate Newbold, Yong Du, Laura Moss, Andrew Hall, Louise Flanagan, Sarah R Brown
Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib in re-sensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. Patients deemed to have sufficient iodine uptake in previously iodine refractory lesions after 4 weeks of Selumetinib therapy will be given an empirical activity of 5...
March 14, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28265769/curcumin-induces-g2-m-arrest-apoptosis-nf-%C3%AE%C2%BAb-inhibition-and-expression-of-differentiation-genes-in-thyroid-carcinoma-cells
#6
Suzan Schwertheim, Frederik Wein, Klaus Lennartz, Karl Worm, Kurt Werner Schmid, Sien-Yi Sheu-Grabellus
PURPOSE: The therapy of unresectable advanced thyroid carcinomas shows unfavorable outcome. Constitutive nuclear factor-κB (NF-κB) activation in thyroid carcinomas frequently contributes to therapeutic resistance; the radioiodine therapy often fails due to the loss of differentiated functions in advanced thyroid carcinomas. Curcumin is known for its anticancer properties in a series of cancers, but only few studies have focused on thyroid cancer. Our aim was to evaluate curcumin's molecular mechanisms and to estimate if curcumin could be a new therapeutic option in advanced thyroid cancer...
March 6, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28237867/exploratory-analysis-of-biomarkers-associated-with-clinical-outcomes-from-the-study-of-lenvatinib-in-differentiated-cancer-of-the-thyroid
#7
Makoto Tahara, Martin Schlumberger, Rossella Elisei, Mouhammed Amir Habra, Naomi Kiyota, Ralf Paschke, Corina E Dutcus, Taro Hihara, Shannon McGrath, Mark Matijevic, Tadashi Kadowaki, Yasuhiro Funahashi, Steven I Sherman
BACKGROUND: Lenvatinib significantly prolonged progression-free survival (PFS) versus placebo in the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT) of patients with radioiodine-refractory differentiated thyroid cancer. This exploratory analysis investigated potential predictive biomarkers of lenvatinib efficacy and target engagement. PATIENTS AND METHODS: Circulating cytokine/angiogenic factors (CAFs) in blood samples collected at baseline and throughout treatment were analysed from patients randomised to receive lenvatinib or placebo from August 5, 2011 to October 4, 2012...
February 23, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28236116/clinical-pharmacokinetic-and-pharmacodynamic-profile-of-lenvatinib-an-orally-active-small-molecule-multitargeted-tyrosine-kinase-inhibitor
#8
Ziad Hussein, Hitoshi Mizuo, Seiichi Hayato, Masayuki Namiki, Robert Shumaker
Lenvatinib is a multikinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor-alpha, and RET and KIT proto-oncogenes. Lenvatinib is approved for the treatment of radioiodine-refractory differentiated thyroid cancer in the United States (US), European Union (EU), Canada, Japan, and Switzerland. It is also approved in combination with everolimus for the treatment of advanced renal cell carcinoma following ≥1 VEGF-targeted treatment in the US and EU...
February 24, 2017: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/28225999/radioactive-iodine-refractory-differentiated-thyroid-cancer-an-uncommon-but-challenging-situation
#9
Angelica Schmidt, Laura Iglesias, Michele Klain, Fabián Pitoia, Martin J Schlumberger
Radioiodine (RAI)-refractory thyroid cancer is an uncommon entity, occurring with an estimated incidence of 4-5 cases/year/million people. RAI refractoriness is more frequent in older patients, in those with large metastases, in poorly differentiated thyroid cancer, and in those tumors with high 18-fluordeoxyglucose uptake on PET/CT. These patients have a 10-year survival rate of less than 10%. In recent years, new therapeutic agents with molecular targets have become available, with multikinase inhibitors (MKIs) being the most investigated drugs...
January 2017: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28213773/radioiodine-treatment-after-surgery-for-differentiated-thyroid-cancer-a-reasonable-option
#10
EDITORIAL
Jérôme Clerc, Frederik A Verburg, Anca M Avram, Luca Giovanella, Elif Hindié, David Taïeb
No abstract text is available yet for this article.
February 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28206679/technical-note-determination-of-individual-thyroid-clearance-effective-half-life-with-a-common-handheld-electronic-dosimeter
#11
Markus Fürstner, Michael Hentschel, Petar-Marko Spanjol, George A Prenosil, Sabine Weidner, Thomas Krause, Bernd Klaeser
PURPOSE: To determine the thyroid clearance effective half-life T with a common handheld electronic dosimeter (ED) in patients undergoing radioiodine treatment for hyperthyroidism. METHODS: Dose rates from 12 inpatients were measured daily with an ED and with a clinical uptake counter. The ED was attached to the patient with two different setups, one using a cervical collar and another employing a neck strap. Estimation of T was performed by linear regression analysis of the log of both the ED and the uptake counter measurements versus time...
February 16, 2017: Medical Physics
https://www.readbyqxmd.com/read/28179619/rituximab-can-induce-remission-in-a-patient-with-ankylosing-spondylitis-who-failed-anti-tnf-%C3%AE-agent
#12
Fahmi AlDhaheri, Talal Almteri, Naji Dwid, Ahd Majdali, Nahed Janoudi, Hani Almoallim
BACKGROUND Ankylosing spondylitis (AS) is a chronic inflammatory disease that predominantly affects the axial skeleton. The ability of anti-TNF-α agents to reduce disease activity in patients with axial spondyloarthritis (axSpA), including AS, has been demonstrated in multiple randomized trials and several meta-analyses. Reports on the efficacy of rituximab in treatment of AS have described good results. We report on a patient with AS who failed anti-TNF-α therapy but showed good clinical improvement with rituximab therapy...
February 9, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28178685/overwhelming-rapid-metabolic-and-structural-response-to-apatinib-in-radioiodine-refractory-differentiated-thyroid-cancer
#13
Yansong Lin, Chen Wang, Wen Gao, Ruixue Cui, Jun Liang
Currently, patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) have limited treatment options. In this study, we aimed to assess the short-term efficacy and safety of apatinib in RAIR-DTC. Ten adult patients were prospectively enrolled to receive oral apatinib (750 mg q.d). The primary endpoints were change in serum thyroglobulin (Tg) concentration, disease control rate (DCR) and objective response rate (ORR) based on RECIST 1.1 criteria. The secondary endpoints included change in glucose metabolism, evaluated by maximum standard uptake value (SUVmax), and safety...
February 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28165859/exercise-induced-hypoxemia-in-juvenile-thyroid-carcinoma-with-lung-metastases
#14
Florian J Segerer, Johannes Biko, Christoph Reiners, Clemens Wirth, Helge Hebestreit
PURPOSE: Exercise-induced arterial hypoxemia (EIAH) has been reported in patients with juvenile thyroid cancer treated with radioiodine for lung metastases. This retrospective study tested the hypothesis that EIAH is due to ventilation-perfusion-mismatch in this rare pulmonary condition. METHOD: 50 patients (age 13 -23 years) treated for juvenile thyroid carcinoma and lung metastasis with 131I and 24 controls with thyroid cancer but without lung metastases and prior 131I-treatment were assessed in a state of acute hypothyroidism by computed tomography of the lungs, pulmonary function testing, cardiopulmonary exercise test with measurements of gas exchange, oxygen saturation, alveolar-arterial difference in pO2 (p(A-a)O2) and pCO2 (p(ET-a)CO2)...
February 6, 2017: Pediatric Exercise Science
https://www.readbyqxmd.com/read/28160320/utility-of-i-124-pet-ct-in-identifying-radioiodine-avid-lesions-in-differentiated-thyroid-cancer-a-systematic-review-and-meta-analysis
#15
REVIEW
Prasanna Santhanam, David Taieb, Lilja Solnes, Wael Marashdeh, Paul W Ladenson
INTRODUCTION: Diagnostic I-123 scans have been shown to underestimate the disease burden in differentiated thyroid cancer (DTC) when compared to I-131 post treatment scans, especially in children and patients who have had prior Radioiodine (RAI) therapy and/or distant metastasis.I-124 PET/CT has been shown to be highly effective in imaging DTC related metastatic disease. METHODS: We performed a systematic review and meta-analysis of studies investigating the sensitivity and specificity of I-124 PET/CT in identifying lesions amenable to RAI therapy as confirmed by I-131 post-treatment scanning...
February 3, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28158908/efficacy-of-low-dose-2-millicurie-versus-standard-dose-4-millicurie-radioiodine-treatment-for-cats-with-mild-to-moderate-hyperthyroidism
#16
J M Lucy, M E Peterson, J F Randolph, P V Scrivani, M Rishniw, D L Davignon, M S Thompson, J M Scarlett
BACKGROUND: Radioiodine ((131) I) is effective treatment for hyperthyroidism in cats, but optimal dose to restore euthyroidism without inducing hypothyroidism is unclear. Treatment-induced hypothyroidism can lead to azotemia and reduced duration of survival. OBJECTIVE: To compare efficacy and short-term outcomes of low-dose (131) I versus higher, standard-dose (131) I as treatment for hyperthyroidism. ANIMALS: A total of 189 client-owned cats undergoing (131) I treatment for mild-to-moderate hyperthyroidism (serum T4 ≥ 4...
March 2017: Journal of Veterinary Internal Medicine
https://www.readbyqxmd.com/read/28149805/radioguided-sentinel-lymph-node-biopsy-in-patients-with-papillary-thyroid-carcinoma
#17
Mattia Portinari, Paolo Carcoforo
BACKGROUND: The ATA guidelines do not recommend prophylactic central compartment neck dissection in patients with T1-T2 papillary thyroid carcinoma (PTC) with no clinical evidence of lymph node metastasis, however patients' staging is recommended. Lymph node metastasis may be present also in small PTC, but preoperative ultrasound identifies suspicious cervical lymphadenopathy in 20-30% of patients. The role of sentinel lymph node biopsy (SLNB) remain open to debate. It has been shown that the identification rate of SLN in PTC patients is improved using a radiotracer compared to a dye technique...
December 2016: Gland Surgery
https://www.readbyqxmd.com/read/28132755/ten-year-experience-of-radioiodine-dosimetry-is-it-useful-in-the-management-of-metastatic-differentiated-thyroid-cancer
#18
F Sun, G E Gerrard, J K Roberts, T Telford, S Namini, M Waller, G Flux, V M Gill
AIMS: When a fixed activity of radioiodine is given for differentiated thyroid cancer (DTC), absorbed doses of radioiodine can vary widely and are not usually measured. Leeds Cancer Centre has routinely used a form of lesion-specific dosimetry for radioiodine patients. This study investigated if the results of dosimetry influenced treatment decisions for patients with advanced DTC. MATERIALS AND METHODS: Since 2005, patients with regionally advanced/metastatic DTC, who underwent radioiodine treatment together with dosimetry, were included in this study...
January 27, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28106465/evaluation-of-99m-tc-mibi-in-thyroid-gland-imaging-for-the-diagnosis-and-classification-of-amiodarone-induced-thyrotoxicosis
#19
Junqi Wang, Ruiguo Zhang
OBJECTIVE: Amiodarone-induced thyrotoxicosis (AIT) is caused by aminodaroneas a side effect of cardiovascular disease treatment. Based on the differences in their pathological and physiological mechanisms, many methods have been developed so far to differentiate AIT subtypes such as color flow Doppler sonography (CFDS)and 24 h radioiodine uptake (RAIU). However, these methods suffer from inadequate accuracy in distinguishing different types of AITs and sometimes lead to misdiagnosis and delayed treatments...
January 20, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28076008/pictorial-review-of-false-positive-results-on-radioiodine-scintigrams-of-patients-with-differentiated-thyroid-cancer
#20
Amy V Chudgar, Jagruti C Shah
Radioiodine has served an important role in the diagnostic workup and treatment of patients with differentiated thyroid cancer for more than 6 decades. The interpretation of radioiodine scintigraphic studies should be performed in conjunction with a comprehensive history, histopathologic correlation, and pertinent laboratory values, as well as correlation with available anatomic images and the findings from physical examination. A thorough understanding of the physiology and biodistribution of radioiodine is critical when interpreting radioiodine scintigraphic studies to avoid misinterpretation of physiologic and nonthyroid pathologic variants as thyroid cancer metastases...
January 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
keyword
keyword
20184
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"